Stryker Corp.: Q3 FY2025 earnings call

What management said about Q3 FY2025, from the documents filed with the SEC on 30 October 2025: press release. Guidance figures: 2 raised. The quarter’s numbers.

Read the filing

Key takeaways

• Net sales up 10.3% to $6.1 billion: Consolidated net sales were $6,057 million, up 10.3% reported and 9.6% in constant currency. Source
• Unit volume drove most organic growth: Organic net sales growth of 9.5% comprised 9.1% from increased unit volume and 0.4% from higher prices. Source
• Adjusted EPS grew 11.1%: Adjusted diluted EPS was $3.19, up 11.1% from $2.87 a year earlier, per the non-GAAP reconciliation. Source
• MedSurg and Neurotechnology up 14.4%: MedSurg and Neurotechnology net sales were $3.8 billion, up 14.4% reported and 13.9% in constant currency. Source
• Adjusted operating margin up 90 bps: Adjusted operating income margin was 25.6%, up 90 bps from 24.7%, after excluding acquisition, amortization, impairment and other items. Source
• Operating cash flow rose to $2.9 billion: Nine-month net cash from operating activities was $2,901 million, against $2,311 million a year earlier. Source

“We delivered another quarter of strong sales and double-digit adjusted earnings per share growth”

Kevin A. Lobo, Chair and CEO

Guidance

What changed from last quarter

• Guidance raised: Full-year 2025 guidance was raised for organic net sales growth and adjusted diluted EPS, from the ranges in the prior release. Source
• Guidance kept: Sales guidance still includes a modestly favorable pricing impact, and foreign exchange is still expected to be slightly positive, as in the prior release. Source

Results and growth drivers

• Net sales up 10.3% to $6.1 billion: Consolidated net sales were $6,057 million, up 10.3% reported and 9.6% in constant currency. Source
• Unit volume drove most organic growth: Organic net sales growth of 9.5% comprised 9.1% from increased unit volume and 0.4% from higher prices. Source
• Nine-month sales rose 11.1%: Nine-month net sales were $17,945 million, up 11.1% from $16,159 million, with constant-currency growth of 10.9%. Source
• Operating income rose, margin fell: Reported operating income was $1,135 million, up 4.6%; the reported operating income margin was 18.7% against 19.7% a year earlier. Source
• Adjusted EPS grew 11.1%: Adjusted diluted EPS was $3.19, up 11.1% from $2.87 a year earlier, per the non-GAAP reconciliation. Source

Segments and regions

• MedSurg and Neurotechnology up 14.4%: MedSurg and Neurotechnology net sales were $3.8 billion, up 14.4% reported and 13.9% in constant currency. Source
• Orthopaedics up 3.9%; 12.5% excluding Spinal: Orthopaedics net sales were $2.3 billion, up 3.9% reported. Excluding the divested Spinal implant business, growth was 12.5% reported and 11.7% in constant currency. Source
• United States outgrew international: United States sales were $4,571 million, up 11.4%; international sales were $1,486 million, up 6.9% reported and 4.3% in constant currency. Source

“Our teams continue to execute at a high level, driving performance at the high-end of MedTech and building sustained momentum across our broad portfolio.”

Kevin A. Lobo, Chair and CEO

Products and customers

• Vascular sales up 59.6%: Vascular net sales were $525 million, up 59.6% reported and 58.9% in constant currency. Source
• Endoscopy sales up 7.0%: Endoscopy net sales were $896 million, up 7.0% reported and 6.7% in constant currency. Source
• Neuro Cranial up 17.6%: Neuro Cranial net sales were $637 million, up 17.6% reported and 17.0% in constant currency. Source
• Trauma and Extremities up 13.0%: Trauma and Extremities net sales were $960 million, up 13.0% reported and 11.9% in constant currency. Source
• Spinal Implants sales fell 96.7%: Spinal Implants net sales were $6 million against $172 million a year earlier, following the divestiture of the Spinal implant business. Source

Costs and margins

• Adjusted operating margin up 90 bps: Adjusted operating income margin was 25.6%, up 90 bps from 24.7%, after excluding acquisition, amortization, impairment and other items. Source
• Adjusted gross margin at 65.0%: Adjusted gross profit margin was 65.0%, against 64.5% a year earlier; reported gross profit margin was 63.6% against 64.0%. Source
• Reported SG&A rose 8.0%: Reported selling, general and administrative expenses rose 8.0% to $2,045 million, or 33.8% of sales; adjusted SG&A was 32.8% of sales. Source
• Impairments reached $73 million: Goodwill and other impairments were $73 million in the quarter, against $2 million a year earlier, mainly asset write-offs and product line exits. Source
• Tariff estimate not restated this quarter: The prior release estimated a 2025 net tariff impact of about $175 million; the current release does not restate that estimate.

“Based on our sales momentum, sustained demand for our products and commitment to margin expansion, we are raising our full year 2025 guidance”

Stryker Corp., press release

Demand and pricing

• MedSurg volume and price both rose: MedSurg and Neurotechnology organic growth of 8.4% included 7.6% from unit volume and 0.8% from higher prices. Source
• Orthopaedics volume offset lower prices: Orthopaedics organic growth of 11.4% included 11.7% from unit volume, partly offset by 0.3% from lower prices. Source
• Sustained demand cited for raised guidance: Management cited sales momentum and sustained demand for its products as the basis for raising full-year guidance. Source

Cash flow and balance sheet

• Operating cash flow rose to $2.9 billion: Nine-month net cash from operating activities was $2,901 million, against $2,311 million a year earlier. Source
• Acquisitions used $4.95 billion: Acquisitions, net of cash acquired, used $4,950 million in the nine months, against $1,598 million a year earlier. Source
• Long-term debt rose $2.7 billion: Long-term debt, excluding current maturities, was $14,845 million at September 30, 2025, against $12,188 million at December 31, 2024. Source
• Cash balance fell to $3.3 billion: Cash and cash equivalents were $3,256 million at September 30, 2025, against $3,652 million at December 31, 2024. Source
• Dividend payments rose to $963 million: Nine-month dividend payments were $963 million, against $914 million a year earlier. Source

Earnings and tax

• Reported diluted EPS rose 2.8%: Reported diluted EPS was $2.22, up 2.8%; nine-month reported diluted EPS was $6.20, down 2.4%. Source
• Effective tax rate fell to 16.5%: The reported effective tax rate was 16.5%, against 20.0% a year earlier; income taxes were $170 million. Source
• Diluted share count edged up: Diluted weighted-average shares were 386.7 million in the quarter, against 385.6 million a year earlier. Source
• Net earnings rose 3.0%: Reported net earnings were $859 million, up 3.0%; nine-month net earnings were $2,397 million, down 2.0%. Source

Acquisitions, strategy and integration

• Vascular renamed after Inari deal: The notes say the Neurovascular business was renamed Vascular in the first quarter of 2025 because of the acquisition of Inari. Source
• Acquisition and integration charges in quarter: Acquisition and integration-related adjustments to operating income were $39 million in the quarter, including $12 million of contingent consideration changes. Source
• Inventory step-up added $61 million: Inventory stepped-up to fair value added $61 million to quarterly cost of sales, and is excluded from adjusted results. Source
• Structural optimization charges in quarter: Structural optimization and other special charges were $41 million in operating income, including $10 million of product line exits. Source

Figures management reported

Risks management discussed

• Financial: Discrete tax items included a $61 million charge tied to transfers of intellectual property between tax jurisdictions in the quarter. Source
• Regulatory: Costs to update quality systems, labeling and products for EU medical device regulations were $11 million of operating charges in the quarter. Source
• Regulatory: Recall-related matters contributed $1 million of operating charges in the quarter and $56 million for the nine months. Source

Earlier plans management reported on

• Not stated: Management cited a commitment to margin expansion as one basis for the raised full-year guidance. Source
• Not stated: The second-quarter release also raised full-year 2025 guidance, citing year-to-date results and operational momentum.

Other quarters

• Q2 FY2026 earnings call
• Q1 FY2026 earnings call
• Q4 FY2025 earnings call
• Q2 FY2025 results

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.